Glp-1 coverage in employer plans could nearly double in 2024

Employer survey: 25% of employers currently offer coverage and most experience positive outcomes; 4 in 10 consider it an immediate concern and intend to offer in 2024; while 21% of hr decision-makers are unaware of glp-1 medications.1 seattle , oct. 9, 2023 /prnewswire/ -- accolade (nasdaq: accd) announced today findings from an employer survey on sentiment and adoption of glp-1 medications. a key finding: while 81% of human resource (hr) decision-makers feel that their employees would be interested, only 25% cover glp-1s today.
ACCD Ratings Summary
ACCD Quant Ranking